HAMBURG (dpa-AFX) - Evotec AG (EVTCY.PK) said Wednesday that CHDI Foundation Inc. has extended and expanded its collaboration with Evotec through to August 2018. Over this period CHDI will fund 55 full-time scientists at Evotec.
The collaboration-which aims to find new treatments for Huntington's disease, an inherited neurodegenerative disorder-will take advantage of additional technologies, capabilities and capacities at Evotec's facilities in Toulouse, France, and Princeton, NJ, USA.
The collaboration was initiated in 2006 and has grown considerably over this period to fully utilise Evotec's best-in-class integrated neuroscience platform.
Evotec provides CHDI with a full range of research activities and expertise in the neuroscience area, including integrated biology and chemistry supported by compound and library management, target validation, stem cell research, high-content screening, computational chemistry, in vitro pharmacokinetics and protein production.
Copyright RTT News/dpa-AFX